Home » Newsletters » BioWorld Science

BioWorld Science

April 7, 1998

View Archived Issues

Elevated plasma P-selectin levels are associated with hypercholesterolemia

Bayer prepares new compounds particularly useful for acute and chronic inflammation

Novel antisecretory/antiulcer agent from Shionogi undergoes evaluation in Japan

Campath-1H enters pivotal phase III testing stage

Metabasis Therapeutics and Pfizer extend ARA research collaboration

FDA approves another new indication for Lovenox

TNT will assess further benefits of Lipitor

More protein tyrosine kinase inhibitors in the pipeline at Glaxo Wellcome

Novel apoptosis-related protease disclosed by Genetics Institute

Inhibitors of MMP enzymes synthesized at American Cyanamid

Novel steroids discovered at Inflazyme are particularly useful for asthma

Interferon-inducing purines disclosed by Japan Energy

Melacine marketing application granted expedited review by EMEA

Biomira announces sale of diagnostics to Centocor

Molecular Biosystems completes phase II trial of Oralex

Orphan Medical announces results of Busulfex clinical trials

Targeted Genetics announces collaboration with NHLBI

Major advance in glaucoma gene research

Megabios acquires rheumatology patent and technology, updates development program

BioTransplant and MedImmune announce patent for MEDI-507 and BTI-322 antibodies

AVI BioPharma and ImmunoTherapy announce preliminary results of phase II vaccine study

Ligand reports positive results of Panretin phase III trial

FDA advisory committee will discuss Aggrastat NDA later this week

Phase Ib results reported for allosteric Hb modifier RSR13

Early clinical trial evaluates orbofiban pharmacodynamics

First clinical trials performed with BMS-181885

HMR files for European, American approval of arthritis drug

Pfizer NK1 antagonist and ondansetron provide synergistic antiemetic efficacy in clinical trials

Merck & Co. designates thrombin inhibitor for clinical development

RPR-130737, a potent nonpeptidyl inhibitor of factor Xa